# Perspective Therapeutics Inc. (CATX) fundamentals

Data as of 2026-09-08. AMEX, United States. Sector: Healthcare / Biotechnology. Price $3.13, market value $357 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Perspective Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 249.2×**. Each dollar of revenue is priced at 249.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.1×**. The shares trade at 1.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -33.9%** (5-yr avg -33.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 100.0%**. Perspective Therapeutics Inc. keeps 100.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Return on equity: -49.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -21.5%**. Return on all capital, debt included, is -21.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -17.4%**. Each dollar of assets produces -17.4% of profit.

## Growth
- **EPS growth (1 yr): -13.8%**. Earnings per share fell 13.8%.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.7×**. It would take 0.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -487.4×**. Operating profit covers interest only -487.4×: fragile.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Perspective Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (15 analysts). 15 analysts cover Perspective Therapeutics Inc.; the consensus is strong_buy, with an average price target of $12.53 (+300% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -11.6%** (YTD 13.8%, 3-mo 3.3%). The shares are down 11.6% over twelve months including dividends.
- **From 52-week high: -49.2%** (59.7% above the low). Trading 49% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.00** (volatility 109%). Beta of 1.00 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CATX · Page: https://foliofundamentals.com/stocks/catx

Not investment advice.